Vaccines

PnuVax Receives Grant to Advance Pneumonia Vaccine

October 02, 2017

A grant from the Bill & Melinda Gates Foundation will advance PnuVax’s pneumonia vaccine’s clinical development and biomanufacturing scale-up using a low-cost manufacturing approach.

J&J and HHS Team Up on Flu Vaccine and Drug R&D

September 20, 2017

Under this partnership, Johnson & Johnson and BARDA will focus on the advanced development of a small-molecule drug and vaccine for the pandemic flu.

FDA Panel Votes Unanimously to Approve GSK Shingles Vaccine

September 14, 2017

Shingrix represents a new, possibly better alternative to existing treatments.

Sanofi Closes Acquisition of Protein Sciences

August 28, 2017

The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.

FDA Seizes Military Vaccine Used in Unauthorized Stem-Cell Treatments

August 28, 2017

FDA halts unproved stem-cell cancer treatments administered to California patients, which was derived from a commercially unavailable military-grade vaccine.

FDA Extends Dynavax’s Hep B Vaccine Review

August 09, 2017

FDA requests more detailed information on a post-marketing study for Dynavax’s hep-B vaccine, which will require an extended review time past its August 2017 PDUFA date.

Merck KGaA and Baylor Partner on Vaccines for Neglected Diseases

August 09, 2017

Through its life-sciences business, MilliporeSigma, Merck KGaA will collaborate with Baylor College of Medicine to advance vaccine development for neglected and emerging diseases.

Janssen, Bavarian Nordic Partner on Hep B and HIV Vaccines

July 31, 2017

Partnership aims to develop new vaccine regimens against hep B and HIV by combining respective proprietary vaccine technologies.

GE, Oritain Partner on Bovine Serum Traceability

July 24, 2017

GE Healthcare partners with Oritain for an independent test that can confirm the country of origin of fetal bovine serum (FBS), a component of biopharmaceutical production.

GSK Ships Seasonal Influenza Vaccines for US Market

July 17, 2017

GSK plans to deliver up to 40 million doses of its quadrivalent flu vaccine for the 2017–2018 season.